ReviewDrugs2004
The role of proton pump inhibitors in gastro-oesophageal reflux disease.
Review in Drugs, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Proton pump inhibitors for chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2020Pooled it
- Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes.Clinica chimica acta; international journal of clinical chemistry · 2008Trial
- Impact of medication use on olfactory performance in older adults.Frontiers in public health · 2025Observational
- Pharmacokinetics of Pantoprazole and Pantoprazole Sulfone in Goats After Intravenous Administration: A Preliminary Report.Frontiers in veterinary science · 2021Article
- Pharmacokinetics and Tissue Levels of Pantoprazole in Neonatal Calves After Intravenous Administration.Frontiers in veterinary science · 2020Article
- Rationale and design of the VISION study: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis.Clinical and experimental gastroenterology · 2018Article
- Persistent gastro-oesophageal reflux symptoms despite proton pump inhibitor therapy.Singapore medical journal · 2016Article
- Unmet Needs in the Treatment of Gastroesophageal Reflux Disease.Journal of neurogastroenterology and motility · 2015Article
- Recent advances in noncardiac chest pain in Korea.Gut and liver · 2012Article
- Comparison of clinical characteristics of patients with gastroesophageal reflux disease who failed proton pump inhibitor therapy versus those who fully responded.Journal of neurogastroenterology and motility · 2011Article
- Anaphylaxis to pantoprazole during general anesthesia.Journal of anesthesia · 2011Article
- Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease.Drugs · 2010Review
- Pantoprazole: a proton pump inhibitor.Clinical drug investigation · 2009Review
- Review
- The value of ambulatory 24 hr esophageal pH monitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard dose anti-reflux medications.Digestive diseases and sciences · 2005Article
- Review
- Review article: oesophageal complications and consequences of persistent gastro-oesophageal reflux disease.Alimentary pharmacology & therapeutics · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The proton pump inhibitors (PPIs) are the most successful class of drugs that have been introduced for the treatment of gastro-oesophageal reflux disease (GORD) because of their profound and consistent effect on gastric acid secretion. The PPIs have demonstrated an excellent adverse effect profile after approximately 18 years of clinical use. Healing rates in erosive oesophagitis surpass 90%. Complete symptom resolution is achievable in close to 80% of patients with Barrett's oesophagus. Complications of these conditions, such as oesophageal stricture, ulceration and others, are becoming less frequent because of PPI treatment. In non-erosive reflux disease, PPIs provide 50-65% symptom response rate, which is the highest amongst all currently available anti-reflux interventions. PPIs have also helped to improve success rates in treating patients with atypical/extra-oesophageal manifestations of GORD. The use of PPI treatment as a diagnostic tool for GORD is well accepted. However, PPIs have changed the face of GORD in the new millennium as the focus in gastroenterology practice has shifted to primarily treating patients who fail PPI therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.